BioSpace News Archive

argenx Launches Phase I trial With Subcutaneous Formulation of ARGX-113

The first subject has been dosed in the Phase I clinical trial.

October 30, 2017

·

5 min read

Deals

Karolinska Development Divests Its Holdings in Xspray and Receives SEK 12.5 Million Directly and Additionally SEK 0.8 Million Via KCIF’s Sale

In September of 2015 Karolinska Development divested its holdings in Xspray to new owners.

October 30, 2017

·

2 min read

Promore Pharma Completes Extensive European Collaboration Regarding DPK-060

One of the results of the project is that Promore Pharma’s DPK-060 has been incorporated into advanced pharmaceutical preparations consisting of nanoparticles with improved efficacy.

October 30, 2017

·

3 min read

Drug Development

BIOPHYTIS Has FDA Approval to Initiate SARA-INT Phase 2b Interventional Study of Sarconeos in Sarcopenia

The approval will enable BIOPHYTIS to begin the SARA-INT interventional study in five clinical centers in the United States.

October 30, 2017

·

6 min read

Make Sure Moisture Analysis Is Accurate With New White Paper From METTLER TOLEDO

October’s e-calendar offer from METTLER TOLEDO will help users learn to ensure reliable halogen moisture analyzer results through an easy, 10-minute routine test.

October 30, 2017

·

1 min read

Policy

INSYS Therapeutics to Record a Minimum Liability for Department of Justice Settlement in Q3 2017

As of Sept. 30, 2017, $150 million has been accrued, which represents our best estimate of the minimum liability exposure we expect to pay over five years.

October 30, 2017

·

3 min read

Policy

INSYS Therapeutics Affirms Its Commitment to Sustainable Future Growth

The company’s CEO has released a statement regarding the events of the past few days.

October 30, 2017

·

2 min read

OrbusNeich’s COMBO Dual Therapy Stent Demonstrates Non-Inferiority vs the Market Leading XIENCE™ Everolimus Eluting Stent

The results showed that the overall incidence of the primary endpoint target vessel failure was lower than the original estimated 9.0%, with 7.0% in the COMBO group vs 4.2% in the Xience group at 12 months, thereby meeting the non-inferiority requirement

October 30, 2017

·

5 min read

Business

INSYS Therapeutics Announces Resignation of Patrick P. Fourteau From Board of Directors

Mr. Fourteau cited personal reasons for stepping down from the board.

October 30, 2017

·

2 min read

Business

Toyota Signs Licensing Agreement with Kazusa DNA Research Institute, Eurofins Genomics, and GeneBay for GRAS-Di DNA Analysis Technology

Toyota’s unique GRAS-Di(1) DNA analysis technology that can dramatically accelerate selective breeding.

October 30, 2017

·

5 min read